Q1 Earnings Forecast for Immunome Issued By Lifesci Capital

Immunome, Inc. (NASDAQ:IMNM) – Equities researchers at Lifesci Capital issued their Q1 2025 earnings estimates for Immunome in a research note issued to investors on Tuesday, March 11th. Lifesci Capital analyst C. Zhu anticipates that the company will earn ($0.61) per share for the quarter. Lifesci Capital currently has a “Outperform” rating and a $20.00 target price on the stock. The consensus estimate for Immunome’s current full-year earnings is ($2.21) per share. Lifesci Capital also issued estimates for Immunome’s Q2 2025 earnings at ($0.61) EPS, Q3 2025 earnings at ($0.67) EPS, Q4 2025 earnings at ($0.73) EPS, FY2025 earnings at ($2.62) EPS, Q1 2026 earnings at ($0.80) EPS, Q2 2026 earnings at ($0.81) EPS, Q3 2026 earnings at ($0.67) EPS, Q4 2026 earnings at ($0.62) EPS and FY2026 earnings at ($2.90) EPS.

Several other equities analysts have also weighed in on the stock. Wedbush restated an “outperform” rating and issued a $33.00 price objective on shares of Immunome in a report on Monday. Piper Sandler cut their target price on shares of Immunome from $23.00 to $21.00 and set an “overweight” rating on the stock in a report on Thursday, November 14th. Six equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus price target of $27.17.

Immunome Price Performance

Shares of NASDAQ IMNM opened at $8.93 on Thursday. The company’s 50 day simple moving average is $10.06 and its 200 day simple moving average is $11.87. Immunome has a fifty-two week low of $8.39 and a fifty-two week high of $26.70. The firm has a market capitalization of $712.41 million, a P/E ratio of -1.10 and a beta of 1.93.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in IMNM. BNP Paribas Financial Markets bought a new position in Immunome in the fourth quarter valued at $70,000. KLP Kapitalforvaltning AS bought a new position in shares of Immunome in the 4th quarter valued at about $75,000. AlphaQuest LLC grew its position in shares of Immunome by 786,700.0% in the 4th quarter. AlphaQuest LLC now owns 7,868 shares of the company’s stock valued at $84,000 after acquiring an additional 7,867 shares during the period. Tower Research Capital LLC TRC grew its position in shares of Immunome by 482.0% in the 4th quarter. Tower Research Capital LLC TRC now owns 8,608 shares of the company’s stock valued at $91,000 after acquiring an additional 7,129 shares during the period. Finally, Aquatic Capital Management LLC bought a new position in shares of Immunome in the 4th quarter valued at about $95,000. Institutional investors own 44.58% of the company’s stock.

Insider Buying and Selling

In other Immunome news, CEO Clay B. Siegall bought 150,000 shares of the firm’s stock in a transaction that occurred on Friday, January 31st. The stock was acquired at an average price of $7.75 per share, with a total value of $1,162,500.00. Following the completion of the transaction, the chief executive officer now owns 669,636 shares in the company, valued at approximately $5,189,679. This trade represents a 28.87 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 8.60% of the stock is currently owned by company insiders.

Immunome Company Profile

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.